Alzamend Neuro announces 1-for-15 reverse stock split to regain Nasdaq compliance

Alzamend Neuro, Inc.

Reverse stock split at 1-for-15 ratio effective 12:01 AM ET on October 31, 2023.
Outstanding shares reduce from ~97M to ~6.47M; par value unchanged at $0.0001.
Split intended to regain compliance with Nasdaq $1.00 minimum bid price requirement.
No fractional shares; cash paid in lieu; new CUSIP 02262M407.
Board approved Oct 17, 2023; stockholders authorized at special meeting Sep 29, 2023.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Alzamend Neuro, Inc.: Filed amendment to certificate of incorporation to effect a one-for-fifteen reverse stock split (effective 2023-10-31).

Change: charter amendment
Effective: 2023-10-31

Exact text from the filing

On October 27, 2023, Alzamend Neuro, Inc. (the “ Company ”), filed an amendment to the Company’s Certificate of Incorporation (the “ Amendment ”) with the State of Delaware to effectuate a reverse stock split of the issued and outstanding shares of the Company’s common stock, $0.0001 par value (“ Common Stock ”) by a ratio of one-for-fifteen (the “ Reverse Stock Split ”).

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-23-014086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.